Provident Financial ServicesNYSE: PFS

Basel, 05 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet' age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect close to 80 million people globally.1-4 The Vabysmo PFS will become available to United States (US) retina specialists and their patients in the coming months.

Vancouver, British Columbia, May 31, 2024 (GLOBE NEWSWIRE) -- Surge Copper Corp. (TSXV: SURG ) (OTCQB: SRGXF ) (Frankfurt: G6D2 ) (“Surge” or the “Company”) is pleased to announce that it has closed its previously announced strategic placement (the “Strategic Placement”) (see April 2, 2024 press release) for gross proceeds of approximately $3.9 million. In addition, the Company announces that it has completed sample selection and shipped the sample material to commence a pre-feasibility study (“PFS”) metallurgy program for the Berg Project.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-cen.

Strategic acquisition of Lakeland Bancorp, high rates, modest loan demand and robust balance sheet will keep supporting Provident Financial (PFS). This makes PFS stock an attractive pick.

PHILADELPHIA and VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces positive clinical data of its lead product candidate, Bria-IMT™, to be presented in one oral presentation session (by Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD), two poster sessions, and one abstract on the updated clinical data of BriaCell's randomized Phase 2 study evaluating Bria-IMT™ in patients with advanced metastatic breast cancers at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place taking place May 31 - June 4, 2024 at McCormick Place, Chicago, IL. The abstracts for these presentations are now available at https://conferences.asco.org/am/abstracts.

Provident Financial (PFS) completes its previously announced merger with Lakeland Bancorp to form a super-community bank in New Jersey.

Players in the Savings and Loan industry such as PFS, RVSB, and WSFS are well positioned to navigate a possible economic downturn and declining loan demand by focusing on digital expansion and strategic acquisitions.

The financial results for Provident Financial (PFS) in the quarter ending March 2024 provide valuable information, but it could be beneficial to analyze certain key metrics against Wall Street predictions and last year's figures.

Provident Financial (PFS) reported earnings of $0.43 per share for the quarter, surpassing the Zacks Consensus Estimate of $0.40 per share. This is lower than the earnings of $0.54 per share from the same period last year.